A Specifically Engineered ADC for HER2+ Metastatic Breast Cancer | OncLive

A Specifically Engineered ADC for HER2+ Metastatic Breast Cancer

September 1, 2020

In this Onclive® webinar, experts will shed light on an approved therapy for adult patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more anti-HER2–based regimens in the metastatic setting. Join us Tuesday, September 16, 2020 at 8 PM EDT.

A Specifically Engineered ADC for HER2+ Metastatic Breast Cancer

Date: Wednesday, September 16, 2020
Time: 8:00 PM ET

Register now!

Join us for an expert-led discussion on an approved therapy for adult patients with unresectable or metastatic HER2+ breast cancer who have received two or more anti-HER2-based regimens in the metastatic setting.

Presented by:

Maria Theodoulou, MD

Medical Oncologist, New York Oncology HematologyAlbany, NY
Clinical Member, Memorial Sloan-Kettering Cancer Center
New York, NY

Sponsored By:


x